The Alport syndrome market was valued at USD 1.46 Billion in 2024 driven by the increasing emphasis on research and development across the 8 major markets. It is expected to grow at a CAGR of 2.40% during the forecast period of 2025-2034 and attain a market value of USD 1.85 Billion by 2034.
Base Year
Historical Year
Forecast Year
The market is expected to expand due to the rising number of reported cases of the condition, particularly in the United States and Europe. The market is poised for growth, driven by increasing demand for genetic therapies, targeted medicines, and personalized medicine options, which are anticipated to improve treatment outcomes in the forecast period.
In September 2023, Calliditas Therapeutics received an Orphan Drug Designation (ODD) from the US FDA for its investigational drug for Alport syndrome. The rising availability of novel therapies will likely accelerate market growth.
The United States is expected to lead the market due to its robust healthcare system, R&D investments, and strong focus on rare disease therapies, all contributing to the market’s growth.
Alport syndrome is a genetic disorder characterized by progressive renal damage, hearing damage, and ocular abnormalities. The kidneys are primarily affected, often leading to end-stage renal disease. The increasing incidence of Alport Syndrome, particularly in America and Europe, has led to rising demand for effective therapeutics. Key trends such as advancements in targeted therapy, increasing clinical research, and growing investments in rare diseases are expected to drive market value in the forecast period.
Rising Prevalence of Alport Syndrome Drives Market Growth
The rising prevalence of Alport syndrome is fuelling the demand for therapies targeting the condition. It is estimated that between 30,000 to 60,000 individuals in the United States are affected by Alport syndrome. The condition is responsible for putting around 1.5% to 3.0% of children on renal replacement therapies in Europe and the United States. The growing prevalence is driving the demand for treatment options, resulting in significant market growth for Alport syndrome therapies.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
Segmentation Based on the Route of Administration to hold a Substantial Market Share
Based on the route of administration, the market is divided into oral, parenteral, and others. Among these, the oral administration is expected to lead the market. Oral medications, such as Tolvaptan, offer ease of use, high patient compliance, and cost effectiveness. They allow for convenient at-home treatment. Oral therapies provide a less invasive and more scalable option for long-term management, ensuring better patient adherence and improved outcomes.
Based on region, the market report covers the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. Among these, the United States is expected to dominate the market due to its robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies. The research and development activities in the pharmaceutical and biotechnology sectors have led to continuous advancements in managing the condition effectively.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Founded in 2014 and headquartered in Lyon, France, the company received an Orphan Drug Designation for its clinical compound Vonafexor for the treatment of Alport syndrome. Vonafexor is being proposed as a fibrolytic and anti-inflammatory drug, aiming at the underlying causes of kidney dysfunction in Alport patients.
Established in 1996, Novartis AG is headquartered in Basel, Switzerland. The company has been active in the rare disease space, including Alport Syndrome. It is developing therapies aimed at improving kidney function and preventing the progression of renal damage in Alport patients, leveraging its extensive research in nephrology and gene therapies.
Founded in 2006, CENTOGENE N.V. is based in Rostock, Germany. The company specializes in rare genetic diseases, including Alport Syndrome. It offers diagnostic services and is developing treatments that focus on precision medicine to improve the management of Alport Syndrome through personalized therapeutic approaches.
Founded in 1973, Sanofi is headquartered in Paris, France. It is committed to advancing treatments for rare genetic diseases, including Alport Syndrome. The company is exploring novel therapies that target the genetic causes of the condition, aiming to slow disease progression and improve kidney health through cutting-edge biopharmaceutical innovations.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include ZyVersa Therapeutics, Inc.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share